Big Pharma Shouts, Generics And Biosimilars Whisper: M&A In 2023
Companies Sit On Dry Powder In Challenging M&A Market
“A lot of companies are hurting because of the higher interest rates,” one major CEO observed recently, summing up a year which saw little headline-grabbing news on the M&A front for generic and biosimilar sponsors.
You may also be interested in...
Ipca Laboratories has completed an open offer for another slice of Unichem, following a recent deal to acquire a third of the company.
Viatris underlined a bold new vision early in 2022 when it announced the sale of its global biosimilars business to Biocon Biologics. Now it has moved to sell its remaining non-core units.
In an acquisition said by both US-based companies to be highly complementary, Azurity Pharmaceuticals has taken control of Slayback Pharma for an undisclosed fee.